GSK PLC (NYSE: GSK) Securities Fraud Class Action

LEAD PLAINTIFF DEADLINE IS APRIL 7, 2025.

If you have suffered losses and would like to discuss your rights, please fill out this form or you may contact Jonathan Naji, Esq. at (484) 270-1453 or via e-mail at [email protected].

Case Background:
A class action lawsuit was filed on behalf of those who purchased or otherwise acquired GSK plc (“GSK”) (NYSE: GSK) American Depositary Receipts between February 5, 2020, and August 14, 2022, inclusive (the “Class Period”).

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects.  Specifically, Defendants misrepresented and/or failed to disclose that: (1) Zantac caused high quantities of NDMA when combined with certain foods; (2) GSK had a heightened risk of legal liability and loss of revenue due to product recalls because of the issues associated with Zantac use; and (3) as a result, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

What is a Lead Plaintiff?

A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case.  Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.